Clinical Trial: Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT04465097) titled 'Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer' on June 30.

Brief Summary: This study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients and explore the genetic model which can predict neoadjuvant endocrine therapeutic results.

Study Type: Interventional

Condition: Breast Cancer

Intervention: * Drug: Tucidinostat

Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26

Other Names:

Chidamide

Epidaza

* Drug: Exemestane

Exemestane: 25 mg QD from week 1 to week 26.

* Drug: Ovarian function suppressi...